Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Seoul National University College of Medicine | UNKNOWN |
| HEM Pharma Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this observational registry study is to compare characteristics of gut and sputum microbiome and metabolome among COPD patients with significant smoking history, COPD patients without significant smoking history and healthy smoker. Additionally, the investigators investigate the difference of blood metabolites and peripheral blood mononuclear cells level among groups.
The main questions it aims to answer are:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COPD patient with significant smoking history | Patients with following conditions
| ||
| COPD patient without significant smoking history | Patients with following conditions
| ||
| Healthy smoker | Patients with following conditions
|
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Shannon diversity index | the investigators will compare alpha diversity and community similarity among groups by using the Shannon diversity index. | At enrollment |
| Simpson index | the investigators will compare alpha diversity and community similarity among groups by using the Simpson index. | At enrollment |
| Principal component analysis | the investigators will compare beta diversity and community similarity among groups by using the principal component analysis. | At enrollment |
| Microbiome composition by metagenomic analysis | The composition of microbiome will be presented as bar graph. | At enrollment |
| Peripheral blood mononuclear cells level | the investigators will compare the Peripheral blood mononuclear cells level among groups | At enrollment |
| Acetic acid level | the investigators will compare the acetic acid level among groups | At enrollment |
| Propionic acid level | the investigators will compare the Propionic acid level among groups | At enrollment |
| Isobutyric acid level |
| Measure | Description | Time Frame |
|---|---|---|
| Difference of microbiome according to Exacerbation | the investigators will investigate the baseline difference of microbiome between COPD patients with moderate to severe exacerbation and COPD patients without moderate to severe exacerbation | within 1 year after enrollment |
| Difference of metabolome according to Exacerbation |
Not provided
Inclusion Criteria:
COPD Patients, defined by FEV1/FVC <0.7, who
Healthy smoker without airflow limitation, defined by FEV1/FVC ≥0.7, who
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
COPD patients with significant smoking history
COPD patients without significant smoking history
Healthy smoker
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
Fecal sample: the investigators will collect fecal sample (≥ 10g) and divided them into stool sample collection kit and OMNIgene GUT OMR-200 Kit (DNA Genotek, Canada).
Sputum sample: the investigators will collect induced sputum sample from each subject. Induction with hypertonic saline (3%) will be performed.
Blood sample: the investigators will retrieve 5cc blood sample from each patient. Blood samples will be centrifuged and stored as plasma and peripheral blood mononuclear cells, respectively.
All samples will be freeze-dried for 24 hours using a benchtop manifold freeze drier and stored at -80°C until analysis.
the investigators will compare the Isobutyric acid level among groups
| At enrollment |
| Butyric acid level | the investigators will compare the butyric acid level among groups | At enrollment |
| Isovaleric acid level | the investigators will compare the Isovaleric acid level among groups | At enrollment |
| Valeric acid level | the investigators will compare the valeric acid level among groups | At enrollment |
| dimethylglycine level | the investigators will compare the dimethylglycine level among groups | At enrollment |
| secondary bile acid level | the investigators will compare the secondary bile acid level among groups | At enrollment |
the investigators will investigate the baseline difference of metabolome between COPD patients with moderate to severe exacerbation and COPD patients without moderate to severe exacerbation |
| within 1 year after enrollment |
| Difference of microbiome according to death | the investigators will investigate the baseline difference of microbiome between COPD patients with death and COPD patients without death | within 1 year after enrollment |
| Difference of metabolome according to death | the investigators will investigate the baseline difference of metabolome between COPD patients with death and COPD patients without death | within 1 year after enrollment |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |